Elisa Yaniz‐Galende
YOU?
Author Swipe
View article: Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Feature plots of relevant immune populations in pre- and post-NACT clusters
View article: Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in GrzB expression min paired samples post-NACT
View article: Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Correlation among the different immune coregulators in pre- and post-NACT tumors
View article: Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in iTME (macrophages/APCS) with NACT in paired samples
View article: Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in iTME (macrophages/APCS) with NACT in paired samples
View article: Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in immune coregulators expression in intraepithelial (ie+) and stromal compartment (s+) in pre- and post-NACT tumors
View article: Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used in the multiplex panels for the detection of the different immune populations
View article: Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Purpose:This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes.Experimental Design…
View article: Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Purpose:This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes.Experimental Design…
View article: Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Patients and diseases baseline characteristics in the CHIVA neoadjuvant trial
View article: Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in GrzB expression min paired samples post-NACT
View article: Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in ieCD8+ and sCD8+ populations in paired samples with NACT
View article: Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used for IHC monomarker detection
View article: Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in ieCD8+ and sCD8+ populations in paired samples with NACT
View article: Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used for IHC monomarker detection
View article: Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in immune coregulators expression in intraepithelial (ie+) and stromal compartment (s+) in pre- and post-NACT tumors
View article: Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Immune cells distribution in post-placebo and post-BIBF tumors
View article: Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Patients and diseases baseline characteristics in the CHIVA neoadjuvant trial
View article: Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Immune cells distribution in post-placebo and post-BIBF tumors
View article: Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used in the multiplex panels for the detection of the different immune populations
View article: Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Correlation among the different immune coregulators in pre- and post-NACT tumors
View article: Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Positivity of immune coregulators in pre- and post-NACT clusters
View article: Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Feature plots of relevant immune populations in pre- and post-NACT clusters
View article: Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Positivity of immune coregulators in pre- and post-NACT clusters
View article: Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Purpose: This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes. Experimental Desi…
View article: PO009/#424 Innovative academic homologous recombination deficiency tests available in advanced ovarian cancer: the European ENGOT initiative
PO009/#424 Innovative academic homologous recombination deficiency tests available in advanced ovarian cancer: the European ENGOT initiative Open
Introduction Recently the PAOLA-1/ENGOT-ov25 phase-3 study (Ray-Coquard ESMO-2022) showed that the addition of olaparib maintenance to 1st-line platinum-based therapy and bevacizumab improved survival of advanced ovarian cancer (AOC) patie…
View article: <scp>RAD51</scp> as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the <scp>RAD51</scp> test
<span>RAD51</span> as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the <span>RAD51</span> test Open
The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence‐based RAD51 test, in different academic labor…
View article: 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative
201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative Open
Introduction/Background* Recently 3 Phase III first-line studies, PAOLA-1/ENGOT-ov25 (Ray-Coquard et al. NEJM 2019). PRIMA/ENGOT-ov26/GOG-3012 (Gonzales Martin et al. NEJM 2019) and VELIA/GOG-3005 (Coleman et al. NEJM 2019) have demonstrat…